Maria-Pilar Barretina-Ginesta

Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer

Ana Oaknin, Anna V. Tinker, Lucy Gilbert et al. · JAMA Oncology · 2020 · 357 citations · Full text

Medicine, Oncology, Pharmacology +16

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial

Shannon N. Westin, Kathleen N. Moore, Hye Sook Chon et al. · Journal of Clinical Oncology · 2023 · 331 citations · Full text

Medicine, Oncology, Pharmacology +12

Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors

Álvaro Lahiguera, Petra Hyroššová, Diana Garzón et al. · EMBO Molecular Medicine · 2020 · 73 citations · Full text

Life Sciences, Cancer Biology, Oncology +17

Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer

Yolanda García García, Ana de Juan Ferré, César Mendiola et al. · International Journal of Gynecological Cancer · 2019 · 56 citations

Medicine, Gynecology, Oncology +17

Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial

Víctor Moreno, Maria-Pilar Barretina-Ginesta, Jesús García-Donás et al. · Journal for ImmunoTherapy of Cancer · 2021 · 54 citations · Full text

Medicine, Oncology, Pharmacology +16